AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
A Multi-Institutional, Phase II Open-Label Study of AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
Sponsor: Amgen
A PHASE2 clinical study on Carcinoid Tumor and Neuroendocrine Tumor, this trial is completed. The trial is conducted by Amgen and has accumulated 8 data snapshots since 2010. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
-
Jan 2018 — Jun 2018 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
▶ Show 3 earlier versions
-
Aug 2017 — Jan 2018 [monthly]
Active Not Recruiting PHASE2
-
Feb 2017 — Aug 2017 [monthly]
Active Not Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE2
First recorded
Mar 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Amgen
- Brigham and Women's Hospital
- Dana-Farber Cancer Institute
- H. Lee Moffitt Cancer Center and Research Institute
- Massachusetts General Hospital
For direct contact, visit the study record on ClinicalTrials.gov .